These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 11933860)

  • 21. End-stage nonalcoholic fatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program.
    Nayak NC; Vasdev N; Saigal S; Soin AS
    Hum Pathol; 2010 Mar; 41(3):425-30. PubMed ID: 19954815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The histologic spectrum of nonalcoholic fatty liver disease.
    Contos MJ; Choudhury J; Mills AS; Sanyal AJ
    Clin Liver Dis; 2004 Aug; 8(3):481-500, vii. PubMed ID: 15331059
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease.
    Yalamanchili K; Saadeh S; Klintmalm GB; Jennings LW; Davis GL
    Liver Transpl; 2010 Apr; 16(4):431-9. PubMed ID: 20373454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The evolution of ideas about nonalcohol fatty liver disease].
    Podymova SD
    Eksp Klin Gastroenterol; 2009; (4):4-12. PubMed ID: 19967814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The spectrum of nonalcoholic fatty liver disease: from steatosis to nonalcoholic steatohepatitis.
    Saadeh S; Younossi ZM
    Cleve Clin J Med; 2000 Feb; 67(2):96-7, 101-4. PubMed ID: 10680276
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Diagnostic criteria for non-alcoholic steatohepatitis].
    Hashimoto E
    Nihon Rinsho; 2006 Jun; 64(6):1025-32. PubMed ID: 16768105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment.
    Milić S; Stimac D
    Dig Dis; 2012; 30(2):158-62. PubMed ID: 22722431
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pediatric nonalcoholic fatty liver disease.
    Lerret SM; Skelton JA
    Gastroenterol Nurs; 2008; 31(2):115-9. PubMed ID: 18391799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
    Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
    Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease.
    Hossain N; Afendy A; Stepanova M; Nader F; Srishord M; Rafiq N; Goodman Z; Younossi Z
    Clin Gastroenterol Hepatol; 2009 Nov; 7(11):1224-9, 1229.e1-2. PubMed ID: 19559819
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD).
    Verma S; Jensen D; Hart J; Mohanty SR
    Liver Int; 2013 Oct; 33(9):1398-405. PubMed ID: 23763360
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are simple noninvasive scoring systems for fibrosis reliable in patients with NAFLD and normal ALT levels?
    McPherson S; Anstee QM; Henderson E; Day CP; Burt AD
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):652-8. PubMed ID: 23325287
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nonalcoholic fatty liver disease.
    Hjelkrem MC; Torres DM; Harrison SA
    Minerva Med; 2008 Dec; 99(6):583-93. PubMed ID: 19034256
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.
    Fracanzani AL; Valenti L; Bugianesi E; Andreoletti M; Colli A; Vanni E; Bertelli C; Fatta E; Bignamini D; Marchesini G; Fargion S
    Hepatology; 2008 Sep; 48(3):792-8. PubMed ID: 18752331
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity.
    Fracanzani AL; Valenti L; Bugianesi E; Vanni E; Grieco A; Miele L; Consonni D; Fatta E; Lombardi R; Marchesini G; Fargion S
    J Hepatol; 2011 Jun; 54(6):1244-9. PubMed ID: 21145841
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Late nonalcoholic fatty liver disease with cirrhosis: a pathologic case of lost or mistaken identity.
    Lefkowitch JH; Morawski JL
    Semin Liver Dis; 2012 Feb; 32(1):92-8. PubMed ID: 22418891
    [TBL] [Abstract][Full Text] [Related]  

  • 37. From nonalcoholic fatty liver to nonalcoholic steatohepatitis and cirrhosis in HIV-infected patients: diagnosis and management.
    Lemoine M; Serfaty L; Capeau J
    Curr Opin Infect Dis; 2012 Feb; 25(1):10-6. PubMed ID: 22183113
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pathophysiology guided treatment of nonalcoholic steatohepatitis.
    Nguyen TA; Sanyal AJ
    J Gastroenterol Hepatol; 2012 Mar; 27 Suppl 2(Suppl 2):58-64. PubMed ID: 22320918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Managing nonalcoholic fatty liver disease: recommendations for family physicians.
    Grattagliano I; Portincasa P; Palmieri VO; Palasciano G
    Can Fam Physician; 2007 May; 53(5):857-63. PubMed ID: 17872748
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Nonalcoholic fatty liver disease: what the pathologist can tell the clinician.
    Brunt EM
    Dig Dis; 2012; 30 Suppl 1():61-8. PubMed ID: 23075870
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.